NOVAVAX INC Form 4 — Glenn Gregory M (Aug. 16, 2021)

Summary

A Form 4 for NOVAVAX INC [NVAX] filed for Gregory M. Glenn, an officer with the title President, R&D, reporting transactions on 08/16/2021 effected under a Rule 10b5-1 trading plan. Under code M the reporting person exercised options for 544 shares at $27.6 and 1,322 shares, bringing direct ownership to 5,927 shares; footnote 2 states the holdings include 1,250 shares acquired under the Amended and Restated 2013 Employee Stock Purchase Plan on July 31, 2021. Code S sales followed at prices from $223.2591 to $248.98, leaving 4,061 shares owned directly. Table II lists the options with expiration dates of 12/15/2027 and 12/13/2028. The form is signed /s/ John A. Herrmann III, Attorney-in-Fact, dated 08/18/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Glenn Gregory M (Last) (First) (Middle) C/O NOVAVAX, INC. 21 FIRSTFIELD ROAD (Street) GAITHERSBURG MD 20878 (City) (State) (Zip) | Glenn Gregory M | (Last) | (First) | (Middle) | C/O NOVAVAX, INC. | 21 FIRSTFIELD ROAD | GAITHERSBURG | MD | 20878 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol NOVAVAX INC [ NVAX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) President, R&D | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | President, R&D
3. Date of Earliest Transaction
 (Month/Day/Year) 08/16/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 08/16/2021 | M (1) | 544 | A | $ 27.6 | 4,605 (2) | D
Common Stock | 08/16/2021 | M (1) | 1,322 | A | $ 46 | 5,927 | D
Common Stock | 08/16/2021 | S (1) | 55 | D | $ 223.2591 (3) | 5,872 | D
Common Stock | 08/16/2021 | S (1) | 57 | D | $ 225.9812 (4) | 5,815 | D
Common Stock | 08/16/2021 | S (1) | 141 | D | $ 227.7858 (5) | 5,674 | D
Common Stock | 08/16/2021 | S (1) | 101 | D | $ 228.7927 (6) | 5,573 | D
Common Stock | 08/16/2021 | S (1) | 219 | D | $ 230.0009 (7) | 5,354 | D
Common Stock | 08/16/2021 | S (1) | 204 | D | $ 231.2702 (8) | 5,150 | D
Common Stock | 08/16/2021 | S (1) | 274 | D | $ 232.1488 (9) | 4,876 | D
Common Stock | 08/16/2021 | S (1) | 153 | D | $ 233.1732 (10) | 4,723 | D
Common Stock | 08/16/2021 | S (1) | 177 | D | $ 234.3777 (11) | 4,546 | D
Common Stock | 08/16/2021 | S (1) | 13 | D | $ 234.88 | 4,533 | D
Common Stock | 08/16/2021 | S (1) | 48 | D | $ 236.2215 (12) | 4,485 | D
Common Stock | 08/16/2021 | S (1) | 63 | D | $ 237.9198 (13) | 4,422 | D
Common Stock | 08/16/2021 | S (1) | 61 | D | $ 239.3215 (14) | 4,361 | D
Common Stock | 08/16/2021 | S (1) | 78 | D | $ 240.37 (15) | 4,283 | D
Common Stock | 08/16/2021 | S (1) | 107 | D | $ 242.9868 (16) | 4,176 | D
Common Stock | 08/16/2021 | S (1) | 50 | D | $ 244.9894 (17) | 4,126 | D
Common Stock | 08/16/2021 | S (1) | 51 | D | $ 246.7173 (18) | 4,075 | D
Common Stock | 08/16/2021 | S (1) | 14 | D | $ 248.98 | 4,061 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (Right to Buy) | $ 27.6 | 08/16/2021 | M (1) | 544 | (19) | 12/15/2027 | Common Stock | 544 | $ 0.00 | 2,587 | D
Stock Option (Right to Buy) | $ 46 | 08/16/2021 | M (1) | 1,322 | (20) | 12/13/2028 | Common Stock | 1,322 | $ 0.00 | 10,592 | D
Explanation of Responses:
1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. Includes 1,250 shares acquired under the Issuer's Amended and Restated 2013 Employee Stock Purchase Plan, as amended, on July 31, 2021.
3. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.23 to $223.33, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.38 to $226.28, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
5. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.30 to $228.28, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
6. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.33 to $229.14, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
7. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.54 to $230.44, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
8. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.81 to $231.765, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
9. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.83 to $232.80, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
10. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.83 to $233.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
11. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233.86 to $234.82, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
12. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.18 to $236.31, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
13. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.63 to $238.56, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
14. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.87 to $239.86, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
15. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.16 to $240.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
16. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.68 to $243.13, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
17. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.86 to $245.04, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
18. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.69 to $246.73, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
19. Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
20. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Remarks:
/s/ John A. Herrmann III, Attorney-in-Fact | 08/18/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_NVAX_4_filed2021-08-18_0001209191-21-052280.xml

Size

39,795 bytes

SHA-256

e548f3694a3ded5b94ee0cf39154e5da30018a175872d6c5a60ce2724cf6e87e

Our copy

SEC_NVAX_4_filed2021-08-18_0001209191-21-052280.xml

Original

www.sec.gov